Loading…
← CockpitCompetitor Analysis › NKTR Nektar TherapeuticsOpen in the cockpit ↗

Nektar TherapeuticsNKTRCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech using PEGylation drug-delivery technology; developing immunology drug rezpegaldesleukin after past oncology setbacks.

Momentum laggard 8
Mkt cap
$1.18B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$23.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-46.0 pp
WACC 11.7%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$34.42
1D-4.2%
1W-10.5%
1M-12.2%
3M-53.8%
6M-50.5%
YTD-18.6%
1Y-42.2%
ATR %5.7%
Beta1.01
52w lowhigh68.4% off high

What Nektar Therapeutics does

Biotech using PEGylation drug-delivery technology; developing immunology drug rezpegaldesleukin after past oncology setbacks.

Has no medicine of its own on sale, so income is limited to royalties and milestone payments from partners whose drugs use its PEGylation technology, with the rest funded from cash raised from investors. After the 2022 failure of its bempegaldesleukin cancer drug with Bristol Myers Squibb, it shrank to focus on immune-disease drugs.

Products and services

  • Rezpegaldesleukin (atopic dermatitis/alopecia)
  • Legacy oncology assets (largely discontinued)

Where it sits in the supply chain

  • Biopharma R&D
  • PEGylated protein/drug-delivery…
  • Immunology & inflammation pipeline

What could go right

  • Positive rezpegaldesleukin data
  • Partnership/licensing deal

What could go wrong

  • History of high-profile trial failures (bempegaldesleukin)
  • Thin pipeline after oncology setbacks

Moat: narrow (IP / patents, process know-how). PEGylation chemistry know-how is real but recent late-stage trial failures have weakened its moat.

Headquarters: San Francisco, California, US · Founded: 1990 · Employees: 63

Named competitors

Nektar Therapeutics at a glance

Size Nektar Therapeutics (NKTR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 2132nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $34.42 on 18 Nov 2026.

Performance Over six months the shares fell 50.5%, against -11.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue fell 16.6% over the last twelve months (peer median +5.9%); the operating margin is -303.6% (peer median 0.8%).

Valuation It trades at 13.3× enterprise value to sales against a peer median of 7.6× (4th most expensive of 18).

Capital Return on invested capital runs 46.0 points below its cost of capital (11.7% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 86NKTR 50
Six months, rebased to 100: Nektar Therapeutics against the median of its 20 peers (local-currency closes).

Nektar Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$52.2M$55.2M$98.4M$90.1M$92.1M
Revenue growth—-44%+9%-2%—
Gross profit$51.5M$54.2M$66.5M$53.5M$62.9M
EBITDA-$158M-$133M-$129M-$130M-$228M
Net income-$177M-$164M-$119M-$276M-$368M
Free cash flow-$257M-$209M-$177M-$193M-$310M
Capital expenditure$528,000$171,000$1.47M$865,000$5.68M
Total debt$129M$149M$194M$230M$258M

Quarterly statements and history in the cockpit →

Nektar Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%68556884436883210009896880623000062616HROW3478504547002550IDIA300026CMHCAVLNGPCR000950VIYASHNKTR6-month return →1-month return →
Up and to the right = strong over both horizons. Nektar Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×68556884436883210009893000062616347850300026CMHCVIYASHNKTRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nektar Therapeutics is the large dot.

Nektar Therapeutics competitors and peer comparison

Head to head with its named competitors (NKTR vs BMY vs LLY vs ABBV)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Nektar Therapeutics NKTR$1.18B-50%-17%-304%13.3×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
Sanofi SAN.PA$114B+13%+15%27%2.6×-4.8%

How Nektar Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nektar Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureNKTRPeer medianRank in peer set
1-month return-12.2%-1.6%5th lowest of 21
6-month return-50.5%-11.8%2nd lowest of 20
Distance from 52-week high-68.4%-36.0%3rd lowest of 21
Revenue growth (TTM)-16.6%+5.9%4th lowest of 18
Operating margin-303.6%0.8%2nd lowest of 18
EV / Sales13.3×7.6×4th most expensive of 18
ROIC minus cost of capital-46.0 pp-7.5 pp4th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%13.3×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%

Questions

Who are Nektar Therapeutics's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Eli Lilly (LLY), AbbVie (ABBV), Sanofi (Dupixent) (SAN.PA). The cockpit's measured peer set (industry) also includes Ascentage Pharma Group International (6855.HK), Chongqing Genrix Biopharmaceutical (688443.SS), Shenzhen Chipscreen Biosciences (688321.SS), Jiuzhitang (000989.SZ), Mabwell (Shanghai) Bioscience (688062.SS), Chongqing Lummy Pharmaceutical (300006.SZ).
Is Nektar Therapeutics expensive compared with its peers?
On ev / sales it trades at 13.3× against a peer median of 7.6×, 4th most expensive of 18 in its peer set.
How has Nektar Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -50.5% against -11.8% for the median peer; over one year -42.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.